Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50%
              by SWOG Cancer Research NetworkCredit: CC0 Public DomainIn exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major patholog          
          
              
              Updated on: April 22,2024
              
              
                  
                  20              
              
              
          
      Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50%
              by SWOG Cancer Research NetworkCredit: CC0 Public DomainIn exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major patholog          
          
              
              Updated on:April 22,2024
              
              
                  
                  20              
              
              
          
      
					